High-dose corticosteroid therapy in COVID-19: the RECOVERY trial - Authors' reply.
Peto L. et al, (2024), Lancet, 403, 1339 - 1340
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2024), Lancet Child Adolesc Health, 8, 190 - 200
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None. et al, (2024), Nat Commun, 15
Community involvement in an outbreak - One year on for mpox.
Cheyne A. et al, (2023), Clin Infect Dis
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2023), Lancet Diabetes Endocrinol, 11, 905 - 914
Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-TS, MIS-C) – report from a randomised, controlled, open-label, platform trial
Landray M. et al, (2023), Lancet Child and Adolescent Health
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk None. and RECOVERY Collaborative Group None., (2023), Lancet, 401, 1499 - 1507
Randomised controlled trials for mpox in endemic countries.
Rojek A. et al, (2023), Lancet Infect Dis
Virus Detection and Identification in Minutes Using Single-Particle Imaging and Deep Learning.
Shiaelis N. et al, (2023), ACS Nano, 17, 697 - 710
Microbial diversity and antimicrobial resistance in faecal samples from acute medical patients assessed through metagenomic sequencing.
Yokoyama M. et al, (2023), PLoS One, 18